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AbsTrACT
Objective Unilateral neglect is a poststroke disorder 
that impacts negatively on functional outcome and lacks 
established, effective treatment. This multicomponent 
syndrome is characterised by a directional bias of 
attention away from contralesional space, together with 
impairments in several cognitive domains, including 
sustained attention and spatial working memory. 
This study aimed to test the effects of guanfacine, a 
noradrenergic alpha-2a agonist, on ameliorating aspects 
of neglect.
Methods Thirteen right hemisphere stroke patients with 
leftward neglect were included in a randomised, double-
blind, placebo-controlled proof-of-concept crossover 
study that examined the effects of a single dose of 
guanfacine. patients were tested on a computerised, 
time-limited cancellation paradigm, as well as tasks that 
independently assessed sustained attention and spatial 
working memory.
results On guanfacine, there was a statistically 
significant improvement in the total number of targets 
found on the cancellation task when compared with 
placebo (mean improvement of 5, out of a possible 
64). however, there was no evidence of a change in 
neglect patients’ directional attention bias. Furthermore, 
Bayesian statistical analysis revealed reliable evidence 
against any effects of guanfacine on search organisation 
and performance on our sustained attention and spatial 
working memory tasks.
Conclusions Guanfacine improves search in neglect 
by boosting the number of targets found but had no 
effects on directional bias or search organisation, nor 
did it improve sustained attention or working memory 
on independent tasks. Further work is necessary 
to determine whether longer term treatment with 
guanfacine may be effective for some neglect patients 
and whether it affects functional outcome measures.
Trial registration number NcT00955253.
InTrOduCTIOn
Up to 80% of patients suffering from right hemi-
sphere stroke exhibit features of unilateral neglect,1 
a syndrome characterised by a directional attention 
bias away from contralesional space.2 3 Neglect leads 
to longer hospitalisation and poorer outcome,4 
but there are no widely accepted therapies.5–7 It 
is not only a disorder of spatial attention but also 
comprises non-spatial attentional deficits.8 One of 
these is impaired vigilance, a reduction in the ability 
to sustain attention over time, which is associated 
with more severe neglect.9 In addition, phasic 
alerting can temporarily reduce patients’ spatial 
bias.10 11 Furthermore, the degree of sustained 
attention deficit correlates inversely with recovery 
in neglect patients,9 raising the possibility that 
neuropharmacological approaches to improving 
sustained attention could reduce the severity of 
neglect.
There is substantial evidence linking vigilance to 
noradrenergic pathways.12 13 Indeed, a small pilot 
study involving three right hemisphere patients 
with chronic neglect reported that a single dose 
of guanfacine (a noradrenergic alpha-2A agonist) 
improved space exploration in two cases.14 Guanfa-
cine is licenced for the treatment of attention-deficit 
hyperactivity disorder (ADHD) and has positive 
effects on behaviour and cognition, including 
sustained attention.15 Remarkably, a single dose 
improves working memory in healthy humans16 
and has also been shown to boost attention and 
working memory in non-human primates.17–19
The previous study of guanfacine in neglect14 
employed both pen-and-paper and computerised 
cancellation tasks, including one that did not allow 
visible marking of cancelled targets-so-called invis-
ible cancellation, which requires patients to retain 
the locations of previously found targets.20 On this 
task, two patients found more targets and explored 
more of the left side of space following guanfacine 
treatment when compared with placebo and base-
line. They also spent more time-on-task, suggesting 
that guanfacine may have acted via an improvement 
in sustained attention. One patient with extensive 
prefrontal damage did not show any improvement 
with guanfacine, in keeping with the finding that 
guanfacine appears to exert its effects via alpha-2A 
receptors in frontal cortex.21 Further evidence for 
an effect of guanfacine on attention impairments 
in adult neurological patients comes from an indi-
vidual with neuroinflammatory disease, whose 
attention deficits responded to regular guanfacine, 
and recurred when the drug was withdrawn.22
To further explore the possible beneficial 
effects of noradrenergic stimulation in neglect, we 
conducted a larger proof-of-concept, randomised, 
double-blind, placebo-controlled crossover investi-
gation of the effects of a single dose of guanfacine. 
In this within-participant design, participants were 
assessed over five consecutive days. To investigate 
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spatial exploration, we employed an invisible cancellation task. 
In contrast to the previous study of guanfacine in neglect, we 
set a fixed time limit to rule out the possibility that patients find 
more targets due to extended search durations. In addition, inde-
pendent tests of sustained attention and working memory were 
administered. A secondary objective was to observe whether 
guanfacine might improve neglect only in patients without 
significant damage to prefrontal cortex.
MeThOds
Patients
Stroke patients with evidence of neglect on bedside testing 
were recruited from Imperial College Healthcare NHS Trust, 
the National Hospital for Neurology and Neurosurgery and 
Northwick Park Hospital. Patients were recruited during their 
inpatient rehabilitation or via the outpatient clinic. As in the 
study by Gorgoraptis and colleagues23 showing the effects of 
the dopamine agonist rotigotine on neglect, we included both 
acute and chronic patients. They were screened for neglect using 
the Mesulam shape24 and Behavioural Inattention Test (BIT) 
star25 cancellation tasks. Patients with robust visual neglect when 
tested twice with these cancellation tests (specifically an overall 
score on one or both tests <75% total and/or five or more omis-
sions on the left than on the right) were considered for inclu-
sion. Patients were initially screened for neglect up to 3 months 
before participation, and then carried out screening cancellation 
tests again immediately prior to participation to ensure that they 
still fulfilled the inclusion criteria. Further inclusion criteria were 
aged >18 years, stroke onset of at least 2 weeks prior to testing 
and ability to give informed consent. See table 1 for more details.
Exclusion criteria were concomitant illnesses that might affect 
interpretation of findings, labile blood pressure following stroke, 
systolic blood pressure <100 mm Hg or diastolic blood pressure 
<70 mm Hg, initiation of new antihypertensive medication 
within 3 weeks before testing, hepatic or renal dysfunction, treat-
ment with neuroleptic medication, diagnosis of brain tumour, 
weight <55 kg, pregnancy or breast feeding, severe coronary 
insufficiency or myocardial infarction in the 6 months prior to 
testing, dysphasia, dementia or any other cognitive or physical 
impairment that would prevent a patient from providing consent 
or performing standard clinical tests for neglect.
Recruitment was terminated after expiry of the drug and 
placebo supply, at which point a total of 13 patients had been 
recruited, 10 of whom had frontal cortical damage of varying 
severity (figure 1A) and 3 of whom had no significant frontal 
cortical damage (figure 1B). Table 1 provides an overview of 
patient demographics and test scores at the time of inclusion.
Procedure
A stratified crossover protocol was employed, allowing for with-
in-patient comparison between treatment and placebo, while 
removing between-patient variability. Oral guanfacine (2 mg; as 
in refs 14 16) was encapsulated by Nova Pharmaceuticals, which 
also provided matching placebo.
Patients were tested on five consecutive days. On days 1, 3 and 
5, they were tested on a task battery that consisted of a comput-
erised ‘invisible’ touchscreen cancellation task,20 plus indepen-
dent tests of sustained attention26 and spatial working memory 
(further details below).
On day 2, individuals received active drug or placebo, and on 
day 4 they received placebo if they had previously received active 
drug and vice versa. The order of administration of guanfacine 
and placebo was counterbalanced across patients, according to a 
pregenerated randomisation scheme. The clinician who admin-
istered the drugs and the tests was blind to the randomisation 
and the drug. The analyses presented here were performed by 




Cancellation test scores at screening Cancellation test scores at time of testing
bIT star Mesulam shape bIT star Mesulam shape
Left right Total Left right Total Left right Total Left right Total
1001 42 27 21 21 42 21 26 47 19 26 45 19 29 48
1002 66 3.25 0 12 12 0 11 11 0 17 17 0 10 10
1003 45 49 15 27 42 5 28 33 11 27 38 2 28 30
1004 58 14 0 14 14 0 13 13 0 18 18 0 14 14
1005 61 33.5 16 26 42 19 30 49 10 24 34 1 23 24
1006 63 2.75 14 27 41 16 15 31 26 27 53 2 29 31
1007 74 6 0 8 8 0 4 4 0 2 2 0 1 1
1008 64 1.25 8 21 29 1 26 27 25 26 51 11 24 35
1009 72 3 27 27 54 24 30 54 19 18 37 1 24 25
1010 74 6 27 27 54 16 28 44 27 24 51 7 28 35
2001 63 7 24 27 51 13 27 40 26 26 52 19 26 45
2002 75 6.5 20 26 46 8 18 26 21 14 35 8 12 20
2003 64 3.75 0 9 9 0 8 8 7 20 27 0 15 15
Figure 1 Individual lesion maps for all 13 participants. patients 1001–
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a different researcher, only after all data were collected. On 
both treatment days, patients were tested on the task battery 
twice: once immediately before guanfacine/placebo administra-
tion and once 2 hours after. As guanfacine is washed out within 
~17 hours, residual effects were not expected to be present by 
day 4 if individuals had received guanfacine on day 2. Patients 
reported no side effects. 
All patients provided informed written consent.
Touchscreen cancellation
Standard cancellation tasks require participants to search for 
and mark targets, leaving a visible ‘cancellation’ of each marked 
target. We employed a touchscreen search task that allowed 
patients to touch targets without marking them14 20. Such an 
invisible cancellation procedure has been shown to be more 
sensitive to neglect than tests with visible markings.27 We used 
three different arrays that were matched in the number and 
distribution of targets (64) and distractors (128) to prevent 
learning of target locations in each array. Each patient saw each 
version only twice and never in direct succession. The order of 
arrays was randomised between patients. A strict time limit of 
2 min was enforced.
As well as recording the total number of targets found, we 
obtained indices of patients’ directional bias and search organ-
isation by employing CancellationTools, a freely available soft-
ware package.28 This provides nearly all previously reported 
cancellation indices and has been used in contemporary neuro-
psychological research. As a measure of general performance, 
we computed the total number of cancelled targets. To examine 
directional bias in spatial attention, we computed the difference 
in the number of cancelled targets on right and left halves of the 
array, as well as the centre of cancellation,29 which is computed 
as the average horizontal position of all cancelled targets (scaled 
so that −1 corresponds with the left-most target, and 1 with the 
right-most).
Although the number of cancelled targets and the directional 
bias were the primary measures of interest, cancellation tasks 
also allow the computation of additional measures. We computed 
the number of revisits. These are targets that patients cancelled 
more than once, either immediately by cancelling the same target 
multiple times in a row or delayed by returning to a target after 
cancelling others. In addition, search organisation was quantified 
by correlating cancellation rank order and corresponding hori-
zontal/vertical locations, the rate of search path intersections, 
the absolute and standardised intercancellation distance and the 
standardised intercancellation angle.
sustained attention
We employed a paradigm in which the targets were red or green 
triangles that pointed downwards, while non-targets were red 
triangles that pointed upwards. Stimuli were presented for 
1000–1500 ms and were interleaved with interstimulus inter-
vals of 1000–1500 ms23 . Patients had to press a button when 
they detected a target, but withhold from pressing when 
non-target stimuli were presented. In total, 320 stimuli were 
shown, of which 40 were green targets, 40 were red targets and 
the remaining 240 were non-targets. The task lasted approxi-
mately 10 min.
As the main outcome measure, we computed response time 
variability, which is commonly used as an index of sustained 
attention, with higher variability indicating poorer deployment 
of attention on task. In order to track patients’ sustained atten-
tion over the course of the test, we binned their correct responses 
into five bins. Each bin contained a minimum of five trials, and 
reaction time variability was calculated as the SD of all response 
times within a bin.
In addition, the task allowed us to compute the propor-
tion of hits, misses, false alarms and correct rejections, as well 
as response sensitivity (d′) and bias (criterion (c)) in terms of 
signal-detection theory.30
spatial working memory
A shortened version of a vertical (non-lateralised) spatial 
working memory task that has previously been used to assess 
neglect patients31 was employed. In each trial, a sequence of 
highlighted locations (circles) was displayed. Locations could 
be presented at any of 10 different positions along the vertical 
midline of the computer screen (five above and five below a 
central fixation cross), but the same location was never repeated 
within a sequence. After observing a sequence, patients were 
presented with a probe display that contained nine black discs 
and a single highlighted location. They were required to verbally 
indicate whether the probed (highlighted) location was part of 
the sequence. Location sequences varied in length from one to 
five stimuli and became progressively longer, with an increase 
of 1 every 10 trials. Thus, trials 1–10 were of sequence length 
1, trials 11–20 were of length 2, and so on until trials 41–50, 
which consisted of sequence lengths of 5 locations. Mean accu-
racy (proportion of correct responses) per sequence length was 
used as the variable of interest.
data analysis
Baseline performance was determined for each patient by aver-
aging scores on days 1, 3 and 5, as well as the preadministration 
sessions on days 2 and 4. Group averages and differences were 
computed between treatment type (baseline, guanfacine and 
placebo) across individuals.
To test whether there was a systematic effect of treatment type, 
we employed repeated-measures analyses of variance (ANOVAs). 
Drug was a factor in all analyses, with three levels: baseline, 
guanfacine and placebo. For the sustained attention task, time 
bins were included as an additional factor, with five levels: one 
for each time bin. This allowed us to assess performance over the 
course of the experiment. For the spatial working memory task, 
sequence length was included as an additional factor, with five 
levels: one for each sequence length.
Traditional (frequentist) repeated-measures ANOVAs produce 
P values, which inform us whether the null hypothesis should be 
rejected or not but not how well it is supported by the data.32 
To address this, we performed Bayesian repeated-measures 
ANOVAs,33 which produce a Bayes factor (BF10). This is the 
probability of the alternative hypothesis (‘guanfacine changes 
patients’ performance’) divided by the probability of the null 
hypothesis (‘guanfacine does not change patients’ performance’). 
In essence, the Bayes factor is a quantification of how much 
confidence one can have in either hypothesis. We interpret our 
results following the guidelines of Jeffreys,34 which considers 
a Bayes factor over 3 as evidence in support of the alternative 
hypothesis. Conversely, a Bayes factor under 1/3 would support 
the null hypothesis.
Data were handled in custom Python35 36 software, using the 
NumPy and SciPy libraries37 for computations and the Matplotlib 
library38 for plotting. All statistical analyses were performed in 
JASP, V.0.7.1.12.39 For the Bayesian analyses, a Cauchy prior of 
0.707 was set (JASP default setting), and it was confirmed for 
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each test that using a wider prior did not affect the direction or 
exaggerate the evidence.
resuLTs
Touchscreen cancellation: general performance
There was a significant main effect of drug on the total number of 
targets found, with a mean of five more targets (out of a possible 
64) cancelled on guanfacine versus placebo, F(2, 24)=5.66, 
P=0.010, ω2=0.26, BF10=4.926. Post hoc paired-sampled 
t-tests revealed a significant improvement in the total number 
of targets found between baseline (M=28.4, SD=13.91) and 
guanfacine (M=31.15, SD=15.09), t(12)=−2.21, P=0.047, 
Cohen’s d=−0.613, BF10=1.687, as well as between the 
placebo (M=26.15, SD=14.29) and guanfacine conditions, 
t(12)=−2.93, P=0.013, Cohen’s d=−0.813, BF10=4.806. 
Importantly, by contrast, there was no significant difference 
between baseline and placebo conditions, t(12)=1.52, P=0.154, 
BF10=0.704. These results provide moderate evidence of a 
significant effect of drug on search performance with the total 
number of targets found increasing by, on average, five on guan-
facine compared with placebo (figure 2A).
Qualitatively, there did not seem to be a difference between 
the patients with (grey lines in figures) and without (orange 
lines) frontal involvement on any of the metrics reported here 
and in the supplementary materials.
Touchscreen cancellation: directional bias
Independent repeated-measures ANOVAs revealed no main 
effect of drug on the difference between the cancellations on 
the right and left sides of the cancellation task (figure 2B), F(2, 
24)=0.39, P=0.683, BF10=0.231, and no main effect of drug on 
the centre of cancellation (figure 2C), F(2, 24)=2.45, P=0.108, 
BF10=0.848. A direct comparison of the difference in right and 
left cancellations in the placebo (M=12.0, SD=7.99) and guan-
facine (M=11.92, SD=11.36) conditions revealed no difference 
between the two, t(12) = 0.03, P=0.976, BF10=0.278.
In sum, these results provide inconclusive evidence for an 
effect of drug on the centre of cancellation, but they do provide 
moderate evidence against an effect of guanfacine on the right 
minus left directional bias.
Touchscreen cancellation: revisits and search organisation
We found no conclusive evidence for an effect of drug on revisits 
(online supplementary figure 1) and moderate evidence against 
there being a main effect of drug in all indices of search organisa-
tion (online supplementary figure 2). Exact test results and direct 
comparisons between guanfacine and placebo can be found in 
the supplementary materials.
sustained attention
A repeated-measures ANOVA revealed no main effect of drug 
on reaction time variability (online supplementary figure 3E). 
FGreenhouse-Geisser(1.38, 16.61)=0.96, P=0.371, BF10=0.100, nor 
a main effect of time, F(4, 48)=0.20, P=0.939, BF10=0.022. 
There was also no interaction between drug and time, F(8, 
96)=0.72, P=0.673. These results provide moderate to strong 
evidence that there was no effect of drug or time on reaction 
time variability in the sustained attention task.
Signal-detection variables were also computed and analysed 
and are reported in the supplementary materials.
spatial working memory
A repeated-measures ANOVA revealed no main effect of drug 
on response accuracy, F(2, 24)=0.84, P=0.446, BF10=0.082, a 
main effect of sequence length, FGreenhouse-Geisser(2.54, 30.42)=6.39, 
P=0.003, ω2=0.30, BF10=28 919.401 and no interaction effect, 
F(8, 96)=1.42, P=0.200. These results provide strong evidence 
that there was no effect of drug on response accuracy and deci-
sive evidence that there was an effect of sequence length on 
response accuracy (with worse accuracy for longer sequences, as 
one might anticipate).
Post hoc paired-sampled t-tests indicated that there was no 
difference between baseline and guanfacine for each sequence 
length (all P>0.05; BF10 for sequence lengths 1, 3, 4 and 5 
ranged between 0.358 and 0.554, and BF10 for sequence length 
2 was 1.533) nor any difference between placebo and guanfa-
cine for each sequence length (all P>0.05; BF10 ranged between 
0.279 and 0.328). For sequence lengths 1–4, there was no differ-
ence between baseline and placebo (all P>0.05, BF10 were 1.183, 
1.116, 0.464 and 0.278 for sequence lengths 1–4, respectively). 
In sum, there was a reliable absence of an effect of treatment 
type on accuracy in the spatial working memory task.
dIsCussIOn
Here we investigated whether a single 2 mg dose of guanfacine, 
an alpha-2A adrenoreceptor agonist, has beneficial effects for 
patients who suffer from unilateral neglect. By supplementing 
frequentist with Bayesian statistics,32 33 we aimed to establish 
whether any null effects were due to guanfacine not being 
different from placebo, or simply due to a lack of statistical 
power. Our results indicate that guanfacine, when compared 
with baseline and placebo, led to a significant improvement in 
Figure 2 Total number of correctly marked targets in a cancellation task (a), as well as the difference between the number of correctly marked targets on 
the right and the left sides of the task (B) and the centre of cancellation where positive values indicate a rightward bias (c) in the baseline (green) condition 
and after placebo (blue) or guanfacine (red) administration. solid horizontal lines indicate the mean, and error bars indicate within-participant 95% cIs. each 
set of three connected dots represents a participant (grey for patients with cortical frontal involvement, and orange for without).
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the total number of targets found on a touchscreen cancellation 
task (mean of 5 out of a possible 64 targets) in which patients 
have to keep track of previously found locations (figure 2). 
However, there was no conclusive evidence as to whether 
guanfacine improved directional bias. Specifically, there was 
moderate evidence that there was no effect of guanfacine on the 
difference between the number of cancellations on the right and 
left sides of the task, but there was no conclusive evidence for 
or against an effect of guanfacine on the centre of cancellation. 
There was also no conclusive evidence for guanfacine affecting 
revisits.
There was moderate evidence for the absence of an effect of 
guanfacine on search organisation, operationalised with four 
indices. In addition, we found moderate to strong evidence that 
guanfacine does not improve response time variability, but no 
conclusive evidence of whether it affects signal detection on a 
sustained attention task. Finally, there was strong evidence that 
guanfacine does not improve spatial working memory.
This study follows on directly from a previous investigation 
in which three neglect patients were tested on an identical 
but time-unlimited ‘invisible’ cancellation task.14 A beneficial 
effect of guanfacine was found for two patients without frontal 
involvement.14 This manifested as a larger number of targets 
found plus increased time-on-task. These findings could have 
been caused by improvement in either or both the directional 
bias and sustained attention components of neglect. In this larger 
sample of 13 neglect patients, we again found an increase in the 
number of targets found on the same computerised visual search 
paradigm following guanfacine. However, we could not demon-
strate statistical evidence for a simultaneous reduction in direc-
tional bias on guanfacine. A larger study with more statistical 
power could potentially address this.
Although there is evidence for the beneficial effects of guan-
facine on working memory in monkeys17 and healthy humans,16 
we found no conclusive evidence that it reduced revisit rates on 
the ‘invisible’ cancellation task. In addition, there was strong 
evidence that guanfacine did not affect accuracy on a vertical 
spatial working memory task.
One interpretation of the findings of Malhotra and colleagues14 
is that guanfacine boosted sustained attention, which caused 
patients to perform the task for longer, increasing the chance that 
they found more targets, without any direct effect on directional 
bias. This is partly supported by the observation that one patient 
whose search improved with guanfacine also showed improve-
ment on a separate non-lateralised sustained attention test.14 
However, we found moderate statistical evidence for the absence 
of an effect of treatment type on sustained attention. Given that 
we employed a strict time limit for the touchscreen search task, 
guanfacine cannot have exerted its effects by modulating time-
on-task in the current study. However, it is still possible that 
guanfacine improved alertness and generalised arousal leading 
to more targets found within the time available. This might also 
account for the lack of any effect on lateralised bias.
Stroke patients with neglect are more likely to also suffer from 
disorganised search,40 41 and some have argued that this is a 
consequence of disturbed spatial attention.42 Across four indices 
of search organisation, we found moderate statistical evidence 
that guanfacine did not result in any improvements.
The previous study of guanfacine in neglect tentatively 
suggested that guanfacine's effects might have longer lasting 
effects than its 17 hours wash-out period would suggest, on the 
basis of one patient doing relatively well on tests 1 week after 
guanfacine administration.14 No such effects appear in the 
current data.
The current study provides further evidence that guanfacine 
modulates search in neglect. However, the benefit is relatively 
small and appears in a highly sensitive test, leaving the exact clin-
ical value unclear. To demonstrate a convincing role for noradren-
ergic therapies, it is essential to evaluate longer term treatment in 
this group, as at present, there is only single-case level evidence 
that regular guanfacine may be effective in reducing attentional 
impairment caused by neurological disease.22 Moreover, given 
that the effect we observed was relatively modest, any further 
study might also profitably explore the effects of increasing 
drug dose. In ADHD, the recommended maximum daily dose is 
0.12 mg/kg compared with the total 2 mg dose used here.
Neglect is considered to be a heterogeneous syndrome, 
consisting of a core directional bias and additional cognitive defi-
cits that increase clinical severity.4 43 As these deficits may not all 
respond to different therapies, and as neglect severity may vary 
on a day-to-day basis, novel trial designs might be particularly 
helpful in determining whether an intervention is efficacious23 
. In particular, we advocate the use of highly precise measures 
in addition to traditional clinical scales. For example, the invis-
ible cancellation task is more sensitive to neglect symptoms and 
provides additional information on domains as working memory 
and executive functioning.28 This information could inform 
whether a drug works and what the underlying cognitive mech-
anism is. It should also be noted that a combination of (phar-
macological and behavioural) interventions might prove more 
efficacious than a single therapy.
COnCLusIOn
We conducted a randomised, double-blind, placebo-controlled, 
crossover study examining the effects of a single 2 mg dose 
of guanfacine, a noradrenergic alpha-2A agonist. Thirteen 
stroke patients with unilateral neglect were tested on an ‘invis-
ible’ cancellation paradigm, as well as sustained attention and 
spatial working memory tasks. A significant improvement in 
the total number of targets patients found on the cancellation 
task was observed on guanfacine versus placebo, but there was 
no evidence for or against beneficial effects of guanfacine on 
directional bias. Guanfacine did not improve search organisation 
and did not affect performance on sustained attention or spatial 
working memory tasks. Further work is now necessary to deter-
mine whether regular treatment with guanfacine has beneficial 
effects on neglect and activities of daily living.
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